V. Belalcázar

发表

Recombinant Erythropoietin and Analogues: A Challenge for Doping Control

J. Segura, E. Llop, C. de Bolós, 2004, Therapeutic drug monitoring.

Induction of integrin β1 expression in bone marrow cells after chemotherapy correlates with the overexpression of lung resistance protein and poor outcome in patients with multiple myeloma

R. Ventura, J. Segura, M. Kitagawa, 2008 .

Urinary di‐(2‐ethylhexyl)phthalate metabolites in athletes as screening measure for illicit blood doping: a comparison study with patients receiving blood transfusion

R. Ventura, J. Segura, N. Monfort, 2010, Transfusion.

Increased FasL expression correlates with apoptotic changes in granulocytes cultured with oxidized clozapine.

Z. Husain, J. Castro, E. Yunis, 2006, Toxicology and applied pharmacology.

Dual morphometrical changes of the deltoid muscle in patients with COPD

J. Gea, M. Orozco-Levi, M. Pastó, 2003, Respiratory Physiology & Neurobiology.

Anti-EPO and anti-NESP antibodies raised against synthetic peptides that reproduce the minimal amino acid sequence differences between EPO and NESP

D. Andreu, B. G. Torre, E. Giménez, 2007, Analytical and bioanalytical chemistry.

Evaluation of protein N‐glycosylation in 2‐DE: Erythropoietin as a study case

J. Segura, G. Gerwig, J. Kamerling, 2007, Proteomics.

Assessing the instability of the isoelectric focusing patterns of erythropoietin in urine

R. Gutiérrez Gallego, J. Segura, E. Llop, 2006, Electrophoresis.

The association between non‐Hodgkin lymphoma and renal cell carcinoma in an HIV‐positive patient: Clinico‐pathological features and pathogenic implications

R. Ventura, J. Segura, J. Pascual, 2008, American journal of hematology.